Vulcan Value Partners LLC Sells 152,866 Shares of Medpace Holdings, Inc. $MEDP

Vulcan Value Partners LLC lessened its position in shares of Medpace Holdings, Inc. (NASDAQ:MEDP) by 76.4% in the fourth quarter, according to its most recent filing with the SEC. The firm owned 47,306 shares of the company’s stock after selling 152,866 shares during the quarter. Medpace makes up approximately 0.5% of Vulcan Value Partners LLC’s investment portfolio, making the stock its 29th largest holding. Vulcan Value Partners LLC owned approximately 0.17% of Medpace worth $26,580,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Optiver Holding B.V. acquired a new stake in shares of Medpace during the third quarter worth $27,000. Steigerwald Gordon & Koch Inc. bought a new stake in Medpace during the fourth quarter valued at $30,000. Elyxium Wealth LLC bought a new stake in Medpace during the fourth quarter valued at $30,000. Quarry LP acquired a new stake in Medpace during the 3rd quarter worth about $35,000. Finally, Bayban acquired a new stake in Medpace during the 4th quarter worth about $44,000. Institutional investors and hedge funds own 77.98% of the company’s stock.

Medpace Price Performance

Shares of MEDP opened at $460.20 on Friday. The stock has a 50-day moving average of $452.12 and a 200-day moving average of $499.49. The company has a market cap of $13.14 billion, a PE ratio of 28.93, a P/E/G ratio of 2.33 and a beta of 1.18. Medpace Holdings, Inc. has a one year low of $301.90 and a one year high of $628.92.

Medpace (NASDAQ:MEDP) last issued its earnings results on Wednesday, April 22nd. The company reported $4.28 EPS for the quarter, beating analysts’ consensus estimates of $3.74 by $0.54. The business had revenue of $706.60 million during the quarter, compared to analyst estimates of $697.82 million. Medpace had a return on equity of 120.89% and a net margin of 17.19%.The firm’s revenue was up 26.5% compared to the same quarter last year. During the same period in the previous year, the company posted $3.67 EPS. Medpace has set its FY 2026 guidance at 16.680-17.500 EPS. Analysts expect that Medpace Holdings, Inc. will post 17.04 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of research analysts have recently issued reports on the company. Robert W. Baird dropped their price objective on Medpace from $565.00 to $477.00 and set an “outperform” rating on the stock in a research note on Friday, April 24th. Royal Bank Of Canada decreased their target price on Medpace from $522.00 to $484.00 and set an “outperform” rating for the company in a research note on Friday, April 24th. BMO Capital Markets lowered their target price on Medpace from $460.00 to $400.00 and set a “market perform” rating for the company in a report on Friday, April 24th. Barclays dropped their price target on Medpace from $500.00 to $450.00 and set an “equal weight” rating on the stock in a research note on Friday, April 24th. Finally, Weiss Ratings cut Medpace from a “buy (b-)” rating to a “hold (c+)” rating in a report on Monday, April 6th. Four investment analysts have rated the stock with a Buy rating, ten have assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Hold” and an average target price of $467.08.

Insider Activity at Medpace

In other Medpace news, General Counsel Stephen P. Ewald sold 16,349 shares of the business’s stock in a transaction on Thursday, May 28th. The shares were sold at an average price of $450.00, for a total transaction of $7,357,050.00. Following the completion of the sale, the general counsel owned 20,343 shares in the company, valued at approximately $9,154,350. The trade was a 44.56% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. 20.50% of the stock is currently owned by corporate insiders.

Medpace Profile

Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.